Tirzepatide is a 39-amino-acid synthetic peptide and a dual agonist of the GIP and GLP-1 receptors, originally developed by Eli Lilly under the designation LY3298176. It has been studied extensively in metabolic research for its relationship to glucose regulation, adiposity, insulin signaling, and food intake behavior across both preclinical and human trial settings. Its dual-incretin architecture marked a notable shift from earlier single-pathway GLP-1 compounds and established the foundation for a broader class of multi-agonist metabolic peptides. Lyophilized powder, 3mL vial. Sold at 20mg and 40mg per vial. For research use only.